| __timestamp | Bristol-Myers Squibb Company | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 660772000 |
| Thursday, January 1, 2015 | 5001000000 | 736435000 |
| Friday, January 1, 2016 | 5002000000 | 775266000 |
| Sunday, January 1, 2017 | 4849000000 | 860348000 |
| Monday, January 1, 2018 | 4551000000 | 814775000 |
| Tuesday, January 1, 2019 | 4871000000 | 942821000 |
| Wednesday, January 1, 2020 | 7661000000 | 985616000 |
| Friday, January 1, 2021 | 7690000000 | 1061508000 |
| Saturday, January 1, 2022 | 7814000000 | 1190423000 |
| Sunday, January 1, 2023 | 7772000000 | 1254234000 |
| Monday, January 1, 2024 | 8414000000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical industry, managing operational costs is crucial for maintaining competitive advantage. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two industry giants: Bristol-Myers Squibb Company and Grifols, S.A., from 2014 to 2023.
Bristol-Myers Squibb, a leader in biopharmaceuticals, has seen its SG&A expenses fluctuate, peaking in 2022 with a 38% increase from 2014. Meanwhile, Grifols, a global healthcare company, has consistently increased its SG&A expenses, marking a 90% rise over the same period.
This trend highlights Bristol-Myers Squibb's strategic cost management, while Grifols' steady increase suggests aggressive expansion and investment in administrative capabilities. Understanding these financial dynamics provides valuable insights into each company's operational strategies and market positioning.
Bristol-Myers Squibb Company vs Alnylam Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Bristol-Myers Squibb Company vs Viking Therapeutics, Inc. Trends and Insights
Bristol-Myers Squibb Company vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Grifols, S.A.
Biogen Inc. or Grifols, S.A.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Genmab A/S or Grifols, S.A.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Grifols, S.A.
Selling, General, and Administrative Costs: Grifols, S.A. vs Ionis Pharmaceuticals, Inc.
Grifols, S.A. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Grifols, S.A. and Veracyte, Inc.
Grifols, S.A. and ImmunityBio, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Taro Pharmaceutical Industries Ltd.